<DOC>
	<DOCNO>NCT00286806</DOCNO>
	<brief_summary>This open-label , multicenter Phase I/II study evaluate safety efficacy single-agent AT-101 men hormone-refractory prostate cancer .</brief_summary>
	<brief_title>A Study Single-Agent AT-101 Men With Hormone Refractory Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Gossypol acetic acid</mesh_term>
	<mesh_term>Gossypol</mesh_term>
	<criteria>1 . Rising PSA , define increase level least two consecutive assessment 2 . ECOG performance status 0 1 3 . Adequate hematologic function 4 . Adequate liver renal function 5 . Able swallow retain oral medication . 1 . Received prior chemotherapy HRPC . 2 . Concurrent therapy treatment prostate cancer . 3 . Clinical sign symptom CNS metastases 4 . Requirement corticosteroid treatment , exception topical corticosteroid inhale corticosteroid reactive airway disease . 5 . Active secondary malignancy history malignancy within last 5 year . 6 . Failure recover toxicity relate prior therapy . 7 . Uncontrolled concurrent illness .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
</DOC>